BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/14/2019 7:58:39 AM | Browse: 127 | Download: 108
Publication Name World Journal of Gastroenterology
Manuscript ID 45668
Country/Territory United States
2019-02-03 14:52
Peer-Review Started
2019-02-06 06:18
To Make the First Decision
2019-03-14 06:21
Return for Revision
2019-03-15 02:49
2019-03-21 18:30
Second Decision
2019-04-04 08:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-04-10 21:42
Articles in Press
2019-04-10 21:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-05-14 00:31
Publish the Manuscript Online
2019-05-14 07:58
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which selected by an in-house editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Clinical Trials Study
Article Title Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients
Manuscript Source Unsolicited Manuscript
All Author List Nicole Loo, Eric Lawitz, Naim Alkhouri, Jennifer Wells, Carmen Landaverde, Angie Coste, Rossalynn Salcido, Michael Scott and Fred Poordad
Author(s) ORCID Number
Nicole Loo http://orcid.org/0000-0001-6360-0909
Eric Lawitz http://orcid.org/0000-0002-4234-224X
Naim Alkhouri http://orcid.org/0000-0001-9872-2391
Jennifer Wells http://orcid.org/0000-0002-1522-3421
Carmen Landaverde http://orcid.org/0000-0002-9133-8212
Angie Coste http://orcid.org/0000-0001-5971-4989
Rossalynn Salcido http://orcid.org/0000-0001-8201-4884
Michael Scott http://orcid.org/0000-0001-9765-1077
Fred Poordad http://orcid.org/0000-0002-1503-1569
Funding Agency and Grant Number
Funding Agency Grant Number
AbbVie B15-791
Corresponding author Fred Poordad, MD, Attending Doctor, Professor, Vice President, Academic and Clinical Affairs, Texas Liver Institute, 607 Camden Street, San Antonio, TX78215, United States. poordad@txliver.com
Keywords HHepatitis C; Ombitasvir; Paritaprevir; Ritonavir; Dasabuvir; Genotype 1
Core Tip The hepatitis C virus (HCV) NS5A inhibitor ABT-267 (ombitasvir, OBV), HCV NS4/4A protease inhibitor ABT-450 (paritaprevir, PTV), CYP3A inhibitor ritonavir (r) and non-nucleoside NS5B polymerase inhibitor ABT-333 (dasabuvir, DSV) (OBV/PTV/r + DSV) with or without ribavirin (RBV) is an approved direct-acting antiviral regimen less frequently studied in an all-comers population. This study included 96 all-comers; many had comorbidities (44.2% hypertensive, 33.7% obese, 20.2% cirrhotic) and 16% previously failed HCV treatment. In these patients, 12 or 24-wk of OBV/PTV/r + DSV +/- RBV was highly effective (99% sustained virologic response for 12 wk treatment), tolerable and resulted in better mental and physical health.
Publish Date 2019-05-14 07:58
Citation Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M and Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239
Url https://www.wjgnet.com/1007-9327/full/v25/i18/2229.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i18.2229
Full Article (PDF) WJG-25-2229.pdf
Full Article (Word) WJG-25-2229.docx
Manuscript File 45668-Review.docx
Answering Reviewers 45668-Answering reviewers.pdf
Audio Core Tip 45668-Audio core tip.m4a
Biostatistics Review Certificate 45668-Biostatistics statement.pdf
Clinical Trial Registration Statement 45668-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form 45668-Conflict-of-interest statement.pdf
Copyright License Agreement 45668-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 45668-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s) 45668-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 45668-Institutional review board statement.pdf
Peer-review Report 45668-Peer-review(s).pdf
Scientific Misconduct Check 45668-Scientific misconduct check.pdf
Scientific Editor Work List 45668-Scientific editor work list.pdf